On 24 March 2021, the applicant also made a request to the Commission for the protection of the following proprietary data: bioavailability study in rats [Annex 37 – Bioavailability study.], toxicological studies (in vitro bacterial reverse mutation assay [Annex 38 – OECD 471 study.], in vivo micronucleus test [Annex 39 – OECD 474 study.] and toxicity studies [Annexes 41 and 42 – OECD 408 study.]) and a randomised, placebo-controlled human study [Annexes 43 and 44 – clinical trial study.].
Recital 4, Regulation (EU) 2024/2694
In forcesince 17 Oct 2024